Results 11 to 20 of about 3,628 (221)

Receptor-Dependent and -Independent Effects of Hemin on Platelet Plasma Membrane Disintegration. [PDF]

FASEB J
Microhemorrhages lead to the release of erythrocytes, which are then degraded and lysed. These hemolyses result in the liberation of free iron‐containing hemin. Hemin induces platelet activation and ferroptosis. Inhibition of GPVI/CLEC‐2 receptor‐mediated ITAM‐signaling inhibits hemin‐induced platelet activation (low hemin concentrations). Deferoxamine,
Laspa Z, Rohlfing AK, Hochuli R, Sowa PW, Castor T, Gawaz MP.   +5 more
europepmc   +2 more sources

Cangrelor [PDF]

Hospital Pharmacy, 2015
Each month, subscribers to The Formulary Monograph Service receive 5 to 6 well-documented monographs on drugs that are newly released or are in late phase 3 trials. The monographs are targeted to Pharmacy & Therapeutics Committees. Subscribers also receive monthly 1-page summary monographs on agents that are useful for agendas and pharmacy/nursing
Dennis J. Cada, Danial E. Baker, Kyle T. Ingram   +2 more
openaire   +2 more sources

Real-World Experience with Cangrelor as Adjuvant to Percutaneous Coronary Intervention: A Single-Centre Observational Study

Cardiology Research and Practice, 2023
Background. Reversible P2Y12 inhibition can be obtained with cangrelor administered intravenously. More experience with cangrelor use in acute PCI with unknown bleeding risk is needed. Objectives. To describe real-world use of cangrelor including patient
Troels Thim, Lars Jakobsen, Rebekka Vibjerg Jensen, Nicolaj Støttrup, Ashkan Eftekhari, Erik Lerkevang Grove, Sanne Bøjet Larsen, Jacob Thorsted Sørensen, Steen Carstensen, Sahar Amiri, Karsten Tange Veien, Evald Høj Christiansen, Christian Juhl Terkelsen, Michael Maeng, Steen Dalby Kristensen   +14 more
doaj   +1 more source

Efficacy of a Combined Antiplatelet Therapy Is Not Affected by a Simultaneous Binding of Cangrelor and PSB 0777 to Albumin

Frontiers in Pharmacology, 2021
Concurrent administration of two drugs may complicate the management of acute coronary syndromes: competitive drug displacement diminishes drug binding and alters drug pharmacodynamics.
Joanna Wzorek, Radosław Bednarek, Cezary Watala, Magdalena Boncler   +3 more
doaj   +1 more source

The P2Y(12) antagonists, 2MeSAMP and cangrelor, inhibit platelet activation through P2Y(12)/G(i)-dependent mechanism. [PDF]

PLoS ONE, 2012
ADP is an important physiological agonist that induces integrin activation and platelet aggregation through its receptors P2Y(1) (Gα(q)-coupled) and P2Y(12) (Gα(i)-coupled). P2Y(12) plays a critical role in platelet activation and thrombosis.
Binggang Xiang, Guoying Zhang, Hongmei Ren, Manjula Sunkara, Andrew J Morris, T Kent Gartner, Susan S Smyth, Zhenyu Li   +7 more
doaj   +1 more source

Cangrelor ameliorates CLP-induced pulmonary injury in sepsis by inhibiting GPR17

European Journal of Medical Research, 2021
Background Sepsis is a common complication of severe wound injury and infection, with a very high mortality rate. The P2Y12 receptor inhibitor, cangrelor, is an antagonist anti-platelet drug.
Qiancheng Luo, Rui Liu, Kaili Qu, Guorong Liu, Min Hang, Guo Chen, Lei Xu, Qinqin Jin, Dongfeng Guo, Qi Kang   +9 more
doaj   +1 more source

Abstract 1122‐000210: Cangrelor to Prevent Intraluminal Thrombosis in Endovascular Therapy for Acute Stroke: Single Center Case Series

Stroke: Vascular and Interventional Neurology, 2021
Introduction: Intraluminal thrombosis after endovascular therapy (EVT) is a peri‐procedural complication that carries a high burden of morbidity and mortality. The use of anti‐thrombotic therapies during EVT remains an evolving field.
Dan Tong Jia, Dan Tong Jia, Ramez Abdalla, Sameer Ansari   +3 more
doaj   +1 more source

Feasibility and safety of cangrelor in patients with suboptimal P2Y12 inhibition undergoing percutaneous coronary intervention: rationale of the Dutch Cangrelor Registry

BMC Cardiovascular Disorders, 2021
Background Despite the advances of potent oral P2Y12 inhibitors, their onset of action is delayed, which might have a negative impact on clinical outcome in patients undergoing percutaneous coronary intervention (PCI).
A. Selvarajah, A. H. Tavenier, W. L. Bor, V. Houben, S. Rasoul, E. Kaplan, K. Teeuwen, S. H. Hofma, E. Lipsic, G. Amoroso, M. A. H. van Leeuwen, J. M. ten Berg, A. W. J. van ‘t Hof, R. S. Hermanides   +13 more
doaj   +1 more source

Advanced pharmacodynamics of cangrelor in healthy volunteers: a dose-finding, open-label, pilot trial

Thrombosis Journal, 2022
Background High on-treatment platelet reactivity (HTPR) remains a major problem in the acute management of ST-elevation myocardial infarction (STEMI), leading to higher rates of stent thrombosis and mortality. We aimed to investigate a novel, prehospital
Georg Gelbenegger, Juergen Grafeneder, Gloria M. Gager, Jolanta M. Siller-Matula, Michael Schwameis, Bernd Jilma, Christian Schoergenhofer   +6 more
doaj   +1 more source

Stabilizing role of platelet P2Y(12) receptors in shear-dependent thrombus formation on ruptured plaques [PDF]

, 2010
Background: In most models of experimental thrombosis, healthy blood vessels are damaged. This results in the formation of a platelet thrombus that is stabilized by ADP signaling via P2Y(12) receptors.
J. J. J. van Giezen, Johan W. M. Heemskerk, Judith M. E. M. Cosemans, Marijke J. E. Kuijpers, Marion A. H. Feijge, Mirjam G. A. oude Egbrink, Paola E. J. van der Meijden, Reyhan Nergiz-Unal, Robert F. Storey, Yu Wang   +9 more
core   +3 more sources